BioLineRx (BLRX) Tops Q3 EPS by 4c

BioLineRx (NASDAQ: BLRX) reported Q3 EPS of ($0.03), $0.04 better than the analyst estimate of ($0.07).

The Company held $38.9 million in cash, cash equivalents and short-term bank deposits as of September 30, 2016.

For earnings history and earnings-related data on BioLineRx (BLRX) click here.

You May Also Be Interested In

• Synopsys upgraded at Piper Sandler on Intel foundry momentum, Apple opportunity
• Bernstein SocGen Reiterates Outperform Rating on Fervo Energy (FRVO)
• RBC initiates GE HealthCare as it sees AI-led innovation cycle driving growth